Products
Pre-Made Insulin Biosimilar, Recombinant Protein targeting INSR: Recombinant therapeutic protein targeting CD220/HHF5 for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-869
Pre-Made Insulin Biosimilar, Recombinant Protein targeting INSR: Recombinant therapeutic protein targeting CD220/HHF5 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Insulin is a peptide hormone produced by beta cells of the pancreatic islets; it is considered to be the main anabolic hormone of the body. It regulates the metabolism of carbohydrates, fats and protein by promoting the absorption of glucose from the blood into liver, fat and skeletal muscle cells. Insulin therapy is often an important part of diabetes treatment.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-869-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-869-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-869-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-869-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Insulin Biosimilar, Recombinant Protein targeting INSR: Recombinant therapeutic protein targeting CD220/HHF5 |
| INN Name | Insulin |
| Target | INSR |
| Format | Recombinant Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | INS (insulin, IDDM1, IDDM2, "insulin-dependent diabetes mellitus 2") 25-54 (Insulin B chain) 90-110 (Insulin A chain) |
| VD LC | INS (insulin, IDDM1, IDDM2, "insulin-dependent diabetes mellitus 2") 25-54 (Insulin B chain) 90-110 (Insulin A chain) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Eli Lilly (Indianapolis IN USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
Facebook
LinkedIn
Twitter
